Teva-Handok acquires domestic approval of asthma/COPD therapy

Published: 2016-03-29 11:44:47

Updated: 2016-04-04 16:06:42

A Handok-Teva’s(CEO Sun-dong Park) asthma and chronic obstructive pulmonary disease(COPD) treatment, Duorespi Spiromax(generic name: budesonide/formoterol) acquired approval from the Ministry of Food and Drug Safety on the 17^th.

An inhaler, Duorespi Spiromax features the increased usage convenience and consistent delivery of the drug. Particularly, once the inhaler’s cover is opened using the...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.

Teva-Handok acquires domestic approval of asthma/COPD therapy

A Handok-Teva’s(CEO Sun-dong Park) asthma and chronic obstructive pulmonary disease(COPD) treatment, Duorespi Spiromax(generic name: budesonide/formoterol) acquired approval from the Ministry of Food and Drug Safety on the 17th.

Fees

A Handok-Teva’s(CEO Sun-dong Park) asthma and chronic obstructive pulmonary disease(COPD) treatment, Duorespi Spiromax(generic name: budesonide/formoterol) acquired approval from the Ministry of Food and Drug Safety on the 17^th.